Skip to main content

Elevated Circulating miRNA150 and miRNA342-3p in Patients with Irritable Bowel Syndrome.

Wednesday, November 06, 2013 — Poster Session I

4:00 p.m. – 6:00 p.m.

FAES Academic Center (Upper-Level Terrace)




  • R.M. Peace
  • R. Longchamps
  • A. Martino
  • B. Majors
  • W.A. Henderson


Background: Irritable Bowel Syndrome (IBS) is a gastrointestinal disorder characterized by chronic abdominal pain (CAP). The discovery of predictive biomarkers of IBS is paramount to the development of effective and nuanced diagnostics. Micro-RNAs (miRNA) are small non-coding RNAs which regulate protein synthesis and may reflect biological dysfunction. This study examined miRNA expression in patients with IBS and healthy controls. Methods: The sample consisted of 43 individuals of which 12 had IBS. RNA was extracted using the PAXGene Blood miRNA kit (Qiagen). 735 miRNAs were quantified by digital detection with the nCounter® Human miRNA Expression Assay (Nanostring). Analyses were done with SPSS, Partek Genomic Suite and Ingenuity Pathway Analysis, with a priori statistical significance set at p≤.05. Results: miRNA150 and miRNA342-3p were found to be significantly (p=0.0008 and p=0.00007) elevated in patients with IBS and after adjusting for the False Discovery Rate. Discussion: miRNA 150 interacts with a protein kinase (AKT2) through which it may affect a number of inflammatory cytokine signaling pathways. miRNA342-3p is predicted to interact with a number of mRNA targets coding for elements involved in pain signaling, synaptic potentiation, and gap junction function all of which may play a role in the CAP component of IBS.

back to top